Risk assessment SOURCES:
2002 Risk factors: age,
family history, male sex, certain dyslipidemias (high LDL with low HDL), very high triglycerides, high levels of small, clumped
LDL, certain chronic infections, tobacco smoking; diabetes mellitus, hypertension, C reactive proteins.
|
|
JK’s skepticism about statins: Statins reduce mortality by about 25%; however, how much is the result of lowering VLDL and how much is
the result of reducing thrombosis is not known. Aspirin’s prevention of
thrombosis reduces overall mortaility of between 22-32% from MI (4 mega studies). The degree of usefullness of statins, other than psychological,
is unclear. Those who take statins already have life-threatening atherosclerosis. Statins cannot reverse this condition, and there effect upon its progression is probably
minimal. Minimal because the plaque formation is mediated by a leucocyte mechanism
in response to certain blood borne chemicals such as nicotine and carbon monoxide. The
association between elevated LDL and disease is probably one of acceleration rather than causal. Mortality figures on intervention for fabric acidsMoreover, it is not the LDL, but rather the clumps of
VLDL (a thing not measured except for research) that is more predictive of continued progression of atherosclorisis. For these reasons, I would recommend 325 mg of aspirin, weight reduction, vigorus
exercise, and a change in diet—in that order. Statins should be reserved for those with very high levels of LDL.
The alternative fibric acids, exetimbe, bile-acid sequestrants, and nician are more natural interventions. (Aspirin reduces major cancers over 20%) This skepticism is supported by a series of Scandinavian studies (only one has shown evidence
of atherosclerotic regression—slight). Wikipedia: “Scandinavian Simvastatin
Survival Study (4S) [16] with over 15 more extending through the more recent ASTEROID [17] trial published in 2006. The first primary prevention comparative treatment trial was AFCAPS/TexCAPS [18] with multiple later comparative statin/placebo treatment trials including EXCEL.[19], ASCOT [20] and SPARCL.[21] [22] While the statin trials have all been clearly favorable for improved human outcomes, only ASTEROID showed evidence
of atherosclerotic regression (slight). For both human and animal trials, those which have shown evidence of disease regression
had all utilized more aggressive combination agent treatment strategies, nearly always
including niacin.”[6] There is further skepticism about the role of diet.
People who do well over-report good diet, and those with corinary disease over-report bad diet—shopping for causal
explanations. Secondly most of the cholesterol is produced in the body. As wikipedia notes: “Dietary changes
to achieve benefit have been more controversial, generally far less effective and less widely adhered to with success. One
key reason for this is that most cholesterol, typically 80-90%, within the body is
created and controlled by internal production by all cells in the body (true of all animals), with typically slighly greater
relative production by hepatic/liver cells. (Cell structure relies on fat membranes to separate and organize intracellular
water, proteins and nucleic acids and cholesterol is one of the components of all animal cell membranes.) While the absolute production quantities vary with the individual, group averages for total human body
content of cholesterol within the U.S. population commonly run about ~35,000 mg (assuming lean build; varies with body weight
and build) and ~1,000 mg/day ongoing production. Dietary intake plays a smaller role, 200-300 mg/day being common values;
for pure vegetarians, essentially 0 mg/day, but this typically does not change the situation very much because internal production
increases to largely compensate for the reduced intake. Both skepticism about diet and statins is supported by the role of tabacco. A person who smokes at least pack a day is 2.09 (in one very well controlled study) more likely to die
from a heart attack in any given year than a non-smoker. The effect of second
had smoke adds further crediance. This has little to do with cholesterol and
LDL and a lot to do with carbon monoxide and other reactive chemicals in tobacco smoke, and the mechanism by which the white
blood cells repond to those chemical—initiating the plaque producing mechanism. Several studies published on the healthfully.org
site are on point. http://healthfully.org/tobacco/id3.html and http://healthfully.org/tobacco/id2.html risk factor of tobacco; http://healthfully.org/nsaids/id2.html, COX-2 inhibitors and the mechanism for atherosclerosis. A number of bio-makers have been
found to be associated with coronary artery disease. The measure of calcium provides
a way to measure the progression of coronary artery disease. The article below
looks into the association of coronary calcium with coronary disease. Journal of the Calcium level in plaque measurement thereof is comparable to selective
coronary angiography for risk of MI. Measuring the Effect of Risk Factors
on Coronary Atherosclerosis: Coronary Calcium Score Versus Angiographic Disease Severity Axel Schmermund MDA, C, *, Dietrich Baumgart MDA, Günter Görge MDA, Dietrich Grönemeyer MDB, Rainer Seibel MDB, Kent R. Bailey PhDC, John A. Rumberger PhD, MD, FACCC, Dietrich Paar MDA and Raimund Erbel MD, FACCA A Department
of Cardiology and Department of Clinical Chemistry and Laboratory Diagnostics, University Clinic B Department
of Radiology and Microtherapy and Institute for Diagnostic and Interventional Radiology, University Witten/Herdecke, Mülheim
an der Ruhr, Germany; C Division
of Cardiovascular Diseases and Internal Medicine and Section of Biostatistics, Mayo Clinic and Foundation, revised accepted Available online Abstract Objectives. This study sought to determine whether
noninvasive quantification of coronary calcium is comparable to selective coronary angiography in measuring the effect of
cardiovascular risk factors on coronary atherosclerosis. Background. Electron beam computed tomography (EBCT)
allows the delineation of anatomic coronary atherosclerotic disease and may be useful for noninvasively defining the role
of established and new cardiovascular risk factors in selected patient groups. Methods. A total of 211 consecutive patients, 26
to 79 years old, referred for evaluation of suspected or recently diagnosed coronary artery disease were examined. Selective
coronary angiography was used to define five angiographic disease categories: normal coronary arteries, nonobstructive disease
and one-, two- or three-vessel disease. EBCT was used to calculate coronary calcium scores, and cardiovascular risk, including
lipid variables and fibrinogen levels, was assessed. Results. Coronary calcium score and angiographic
disease severity categories were largely predicted by identical risk factors (i.e., age, male gender, total/high density lipoprotein
cholesterol ratio, fibrinogen) and, to a lesser degree, hypertension. Only smoking predicted angiographic disease severity
but not calcium scores. The risk factors together explained a comparable proportion of the variability in angiographic disease
categories and in calcium score quintiles (33% vs. 41%, p = 0.16 by bootstrap analysis). An overall risk score composed of
these risk factors separated angiographic disease categories and calcium score quintiles with a similar area under the receiver
operating characteristic curve ([mean ± SE] 0.81 ± 0.03 vs. 0.83 ± 0.03, p = NS). Conclusions. Quantification of coronary calcium
is comparable to selective coronary angiography in measuring the effect of established cardiovascular risk factors on coronary
atherosclerosis. Thus, EBCT may be useful for the noninvasive evaluation of the relations between conventional or developing
cardiovascular risk factors and coronary atherosclerosis From the complete article: Coronary Calcium and atherosclerosis Several mechanisms link arterial
calcification to atherosclerosis. Cholesterol and its oxidation products accelerate
coronary calcification. Smaller amounts of calcium have been shown to be present
in noncomplex, lipid-rich fibromuscular plaques and in coronary lesions seen in young adults (type iii lesion). More advanced type Vb/Vii plaques regularly contain calcium deposits.
Although calcium quantitites are best correlated with overall coronary plaque area, a positive correlation with stenosis
severity is also seen, establishing the potential for noninvasive diagnosis or coronary stenosis. In contrast, even severe stenosis are occasionally non-calcified as assessed by EBCT. Coronary angiography very reliably detects flow-limiting stenoses.
Overall plaque burden may be underestimated because of mechanisms such as arterial remodeling, a diffuse distribution
of atherosclerotic disease and eccentric lesion formation. In this respect, sophisticated
angiographic scoring methods seem to offer only limited incremental value. Smoking was independently associated with
angiographic disease but not with coronary calcium score. Smoking is a risk factor for coronary arterial thrombosis irrespective
of plaque morphology, and it may lead to clinical symptoms at earlier stages of coronary artery disease than in nonsmokers.
Accordingly, smokers with a comparably low coronary plaque burden and little or no calcification may become symptomatic. An interesting finding in our study group
was the strong independent predictive value of fibrinogen levels with respect to both calcium scores and angiographic disease
categories. It has been previously shown that elevated fibrinogen levels independently predict cardiovascular events. Its role as an indicator of inflammation notwithstanding, elevated fibrinogen levels
can be considered a major cardiovascular risk factor. Recent reports have suggested that chronic infection with
agents such as Chlamydia pneumoniae may play a role in vascular endothelial damage and atherogenesis. Homocystein concentrations have been associated with premature
coronary artery disease and myocardial infraction. EBCT may allow noninvasive evaluation of the relation between conventional
or developing cardiovascular risk factors and coronary atherosclerosis. Those who have a financial interest in the outcome manipulate the results, Major study finds that all 37 journal articles positive effects over stated; the average was 32%. Statins cause erectile
dysfunction, cognitive imparement, and cancer. Lipitor (2011) lifetime sales $131
billion, tops all drugs. Plavix at
$60 billion is second. STATINS CANCER Link 52% short term LA Times, Health section, Vytorin, the
combination drug (simvastatin (better known by its commercial name Zocor) and ezetimibe--known as Zetia) prescribed to lower
cholesterol, sustained another blow today, when the author of a major clinical trial announced that the medication had failed
to drive down hospitalization and death due to heart failure in patients with narrowing of the aortic valve. In the process,
researchers in Today's findings
suggested something more ominous: the incidence of cancer -- and of dying of cancer -- was significantly higher in the patients
taking Vytorin. Altogether, 67 patients on placebo developed cancer during the trial.
Among subjects on Vytorin, 102 developed cancers of various kinds.* This
is the second adverse press—the first being in March 08, when the ENHANCE trial found that Vytorin fared no better than
a placebo at reducing plaque buildup on the walls of patients' arteries.* * Comments
by jk Simvastatin (Zocor) is off patent. Thus in a scramble for profits a combination drug (on patent) was introduced. Direct to consumer market cost $155 in 07—mainly TV ads. *
The pressing issue is that since the development of Statins, the very
first animal studies in the 60s it has been known that Statins increase the incidents of cancer. However, nearly all studies done thereafter have not included cancer.
*
Several studies have failed to find a reduction in the build of plaque, even thought the statins including Zocor, reduce
EXTENDED RELEASE NIACIN IS A SAFER, AND A MORE EFFECTIVE WAY TO LOWER
MI RISK! |